Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PARG | Q86W56 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PKLR | P30613 | 1/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678944 | 0.94 | PDE1B (0.36) | MAOBPARGNPBWR1PDE1BPDE2A | |
| SCHEMBL674937 | 0.88 | PDE1B (0.37) | MAOBPARGNPBWR1PDE1BPDE2A | |
| SCHEMBL675577 | 0.86 | GRM2 (0.42) | MAOBNPBWR1PPARAPKMLMNA | |
| SCHEMBL676380 | 0.85 | PDE1B (0.49) | PARGPDE1BPDE2APDE4DPKM | |
| SCHEMBL680616 | 0.83 | PDE1B (0.44) | PARGPDE1BPDE2APDE4DPDE1A | |
| SCHEMBL680009 | 0.82 | PDE1B (0.37) | MAOBPDE1BPDE2APDE4DABCC8 | |
| SCHEMBL676509 | 0.81 | DPP4 (0.39) | PDE1BPDE2APDE4DPPARDPPARA | |
| SCHEMBL676450 | 0.80 | PDE1B (0.52) | PDE1BPDE2APDE4DLMNATSHR | |
| SCHEMBL15943438 | 0.79 | PDE1B (0.38) | PDE1BPDE2APDE4DTSHRPDE1A | |
| SCHEMBL674429 | 0.74 | ALDH1A1 (0.43) | NPBWR1PKMLMNAGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289518-A1 | METHOD FOR TREATING BRAIN OR NERVE INJURY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-09-17 | — | — | US | disclosed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-9801882-B2 | Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9487527-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20150374699-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150119370-A1 | Organic Compounds | LI PENG (US) | 2015-04-30 | — | — | US | disclosed |
| US-8859564-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859564-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859564-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2367430-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2367430-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20110281832-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110281832-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289518-A1 | METHOD FOR TREATING BRAIN OR NERVE INJURY | GAP43, NGF, CHAT | MAOB 468/4885PARG 3509/4885NPBWR1 523/4885 |
| US-20150374699-A1 | NOVEL USES | PDE2A, PDE5A, PDE3A | MAOB 472/4885PARG 667/4885NPBWR1 1802/4885 |
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | MAOB 642/4885PARG 393/4885NPBWR1 686/4885 |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | PDE5A, PDE3A, PDE2A | MAOB 433/4885PARG 184/4885NPBWR1 859/4885 |
| US-20110281832-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | MAOB 297/4885PARG 1290/4885NPBWR1 4859/4885 |
| US-20150119370-A1 | Organic Compounds | CYP2C19, CYP2C9, CYP3A43 | MAOB 55/4885PARG 1989/4885NPBWR1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.